Unique ID issued by UMIN | UMIN000048000 |
---|---|
Receipt number | R000054719 |
Scientific Title | Suppressive effects of orally ingested tomato-derived dietary fibers on postprandial blood triglyceride levels: a systematic review with meta-analysis. |
Date of disclosure of the study information | 2023/12/31 |
Last modified on | 2023/06/13 11:37:58 |
Suppressive effects of orally ingested tomato-derived dietary fibers on postprandial blood triglyceride levels: a systematic review with meta-analysis.
Suppressive effects of tomato-derived dietary fibers on postprandial blood triglyceride levels: a systematic review.
Suppressive effects of orally ingested tomato-derived dietary fibers on postprandial blood triglyceride levels: a systematic review with meta-analysis.
Suppressive effects of tomato-derived dietary fibers on postprandial blood triglyceride levels: a systematic review.
Japan |
Healthy adults
Adult |
Others
NO
To evaluate whether orally ingested tomato-derived dietary fibers suppress postprandial blood triglyceride levels in healthy adults.
Efficacy
Others
Others
Not applicable
Postprandial blood triglyceride levels, delta blood triglyceride levels, area under the curve calculated based on the change of delta blood triglyceride levels, the peak value of delta blood triglyceride levels
Others,meta-analysis etc
18 | years-old | <= |
Not applicable |
Male and Female
(PICOS)
Participant:
Healthy adults without illness (excluding pregnant women (including those planning to become pregnant) and lactating women)
Intervention:
Oral intake of test food containing tomato-derived dietary fiber (regardless of the form of intake)
Comparison:
Oral intake of test food without tomato-derived dietary fibers, or no intervention
Outcome measurement:
Postprandial blood triglyceride levels, delta blood triglyceride levels, area under the curve calculated based on the change of delta blood triglyceride levels, the peak value of delta blood triglyceride levels
Study design:
Randomized controlled parallel trials (RCT-P), randomized controlled crossover trials (RCT-C), quasi- randomized controlled parallel trials (qRCT-P), quasi randomized controlled crossover trials (qRCT-C), non-randomized controlled parallel trials (nonRCT-P), non-randomized controlled crossover trials (nonRCT-C), and non-randomized controlled trials
(Language)
Eligibility is not restricted by language.
Exclude proceedings and unpublished studies which don't give us enough research details, and other gray documents that are difficult to verify.
1st name | Takuro |
Middle name | |
Last name | Inoue |
KAGOME CO., LTD.
Innovation Division
3292762
17 Nishitomiyama, Nasushiobara-shi, Tochigi
0287-36-2935
g167_0@kagome.co.jp
1st name | Kazutaka |
Middle name | |
Last name | Yoshida |
KAGOME CO., LTD.
Innovation Division
3292762
17 Nishitomiyama, Nasushiobara-shi, Tochigi
0287-36-2935
g167_0@kagome.co.jp
KAGOME CO., LTD.
None
Self funding
Kagome research ethics committee
3-21-1 Nihonbashihamacho, Chuo-ku, Tokyo, 103-8461
03-5623-8501
toshika_okuni@kagome.co.jp
NO
2023 | Year | 12 | Month | 31 | Day |
Published
202
Main results already published
2022 | Year | 06 | Month | 07 | Day |
2022 | Year | 06 | Month | 08 | Day |
2022 | Year | 06 | Month | 09 | Day |
2022 | Year | 12 | Month | 31 | Day |
Research papers will be searched for 8 databases from the beginning of each database to the search date by two reviewers. To increase the comprehensiveness, the studies whose existence has been revealed by hand search, requotation, or other methods will be added to the review.
Screening and data extraction based on eligibility criteria (PICOS) will be conducted independently by two reviewers. Disagreements and uncertainties will be resolved by discussion between the reviewers or final decision by another reviewer
Assessment of the quality and evaluation of the indirectness of articles will be conducted independently by two reviewers. A full quality appraisal of these papers will be made using modified check list (13 items) of Cochrane Handbook for interventional trials. Disagreements and uncertainties will be resolved by discussion between the reviewers or final decision by another reviewer The agreement rate and the kappa coefficient will be calculated to determine the degree of agreement. Studies evaluated as having a high risk of bias will not be adopted.
A meta-analysis will be performed using EZR or RevMan by a reviewer only in the absence of heterogeneity. Studies with missing or uncertain data will be excluded if no data is available by contacting the author. If not suitable for integration, a qualitative assessment will be carried out. Estimated heterogeneity and publication bias will be assessed from I square value in Forest plot and Funnel plot, respectively. Sensitivity analysis and subgroup analysis will be performed as necessary.
Imprecision will be assessed based on the total number of participants in all included studies.
Inconsistency will be evaluated for the I square value and by statistical test for heterogeneity of effect estimates in a meta-analysis. If a meta-analysis cannot be performed, inconsistency will be assessed from the percentage of studies that have had a significant effect.
2022 | Year | 06 | Month | 09 | Day |
2023 | Year | 06 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054719